{"entity":{"id":"nct06829771","kind":"trial","name":"Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma","aka":[],"tldr":"A phase 1/2 trial of TQB2825 in diffuse large b-cell lymphoma, run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., now recruiting.","summary":"Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma is a phase 1/2 interventional study registered as NCT06829771 by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., with 90 participants planned, started 2025-04-23 and due to reach its primary completion in 2026-05. Interventions recorded: TQB2825 injection +R-CHOP regimen, TQB2825 injection + GemOx. Conditions listed: Diffuse Large B Cell Lymphoma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06829771","url":"https://clinicaltrials.gov/study/NCT06829771"}],"tags":["ctgov-ingest"],"related":[],"cancers":["dlbcl"],"sections":[],"technologies":[],"targets":[],"drugs":["tqb2825"],"companies":["sino-biopharm"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06829771","phase":"1/2","setting":"Phase Ib/II Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","enrolled":90,"outcomes":[]},"route":"/trials/nct06829771/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"drug":[{"id":"tqb2825","kind":"drug","name":"TQB2825","route":"/drugs/tqb2825/"}],"company":[{"id":"sino-biopharm","kind":"company","name":"Sino Biopharmaceutical (Chia Tai Tianqing)","route":"/companies/sino-biopharm/"}]}}